Furst DE - Search Results

1

Twenty-two points to consider for clinical trials in systemic sclerosis, based on EULAR standards.

Khanna D, Furst DE, Allanore Y, Bae S, Bodukam V, Clements PJ, Cutolo M, Czirjak L, Denton CP, Distler O, Walker UA, Matucci-Cerinic M, Müller-Ladner U, Seibold JR, Singh M, Tyndall A. Khanna D, et al. Among authors: furst de. Rheumatology (Oxford). 2015 Jan;54(1):144-51. doi: 10.1093/rheumatology/keu288. Epub 2014 Aug 13. Rheumatology (Oxford). 2015. PMID: 25125594 Free PMC article. Review.

2

Association of HLA antigen a9 with progressive systemic sclerosis (scleroderma).

Clements PJ, Opelz G, Terasaki PI, Mickey MR, Furst D. Clements PJ, et al. Tissue Antigens. 1978 Apr;11(4):357-61. doi: 10.1111/j.1399-0039.1978.tb01268.x. Tissue Antigens. 1978. PMID: 78536

3

Echocardiographic features of progressive systemic sclerosis (PSS). Correlation with hemodynamic and postmortem studies.

Smith JW, Clements PJ, Levisman J, Furst D, Ross M. Smith JW, et al. Am J Med. 1979 Jan;66(1):28-33. doi: 10.1016/0002-9343(79)90478-9. Am J Med. 1979. PMID: 154294 No abstract available.

4

Measurement of clinical change in progressive systemic sclerosis: a 1 year double-blind placebo-controlled trial of N-acetylcysteine.

Furst DE, Clements PJ, Harris R, Ross M, Levy J, Paulus HE. Furst DE, et al. Ann Rheum Dis. 1979 Aug;38(4):356-61. doi: 10.1136/ard.38.4.356. Ann Rheum Dis. 1979. PMID: 386962 Free PMC article. Clinical Trial.

5

Why everything (or nothing) seems to work in the treatment of scleroderma.

Seibold JR, Furst DE, Clements PJ. Seibold JR, et al. Among authors: furst de. J Rheumatol. 1992 May;19(5):673-6. J Rheumatol. 1992. PMID: 1613694 No abstract available.

6

Cardiac score. A semiquantitative measure of cardiac involvement that improves prediction of prognosis in systemic sclerosis.

Clements PJ, Lachenbruch PA, Furst DE, Paulus HE, Sterz MG. Clements PJ, et al. Among authors: furst de. Arthritis Rheum. 1991 Nov;34(11):1371-80. doi: 10.1002/art.1780341105. Arthritis Rheum. 1991. PMID: 1835389

7

Elevated serum levels of soluble interleukin 2 receptor, interleukin 2 and neopterin in diffuse and limited scleroderma: effects of chlorambucil.

Clements PJ, Peter JB, Agopian MS, Telian NS, Furst DE. Clements PJ, et al. Among authors: furst de. J Rheumatol. 1990 Jul;17(7):908-10. J Rheumatol. 1990. PMID: 2213757

8

Skin score. A semiquantitative measure of cutaneous involvement that improves prediction of prognosis in systemic sclerosis.

Clements PJ, Lachenbruch PA, Ng SC, Simmons M, Sterz M, Furst DE. Clements PJ, et al. Among authors: furst de. Arthritis Rheum. 1990 Aug;33(8):1256-63. doi: 10.1002/art.1780330828. Arthritis Rheum. 1990. PMID: 2390128

9

Home central venous hyperalimentation in fifteen patients with severe scleroderma bowel disease.

Ng SC, Clements PJ, Berquist WE, Furst DE, Paulus HE. Ng SC, et al. Among authors: furst de. Arthritis Rheum. 1989 Feb;32(2):212-6. doi: 10.1002/anr.1780320216. Arthritis Rheum. 1989. PMID: 2493254

10

Immunosuppression with chlorambucil, versus placebo, for scleroderma. Results of a three-year, parallel, randomized, double-blind study.

Furst DE, Clements PJ, Hillis S, Lachenbruch PA, Miller BL, Sterz MG, Paulus HE. Furst DE, et al. Arthritis Rheum. 1989 May;32(5):584-93. doi: 10.1002/anr.1780320512. Arthritis Rheum. 1989. PMID: 2655606 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

735 results

Search Page

Filters